Anti-clever-1 agents for controlling lysosomal vatpase proton pumps to increase lysosomal ph-value and the cross-presentation of digested matter
WO2021058866A1
Method for determining potency of therapeutic anti-clever-1 antibody
WO2020115368A1
Method for determining patient's responsiveness to type i interferon treatment and use of type i interferon to treat patient having specified single nucleotide polymorphism
AU2019370785A1
TLR9 agonists for use in downregulating clever-1 expression on alternatively activated macrophages
AU2019293858A1
Treatment of cancer with CLEVER-1 inhibition in combination with PD-1/PD-L1 inhibitor
EP3445786A1
Diagnosis of immune_activation using clever-1, tnf-alpha and hla-dr binding agents
KR20180134876A
Humanized Anti-CLEVER-1 Antibodies and Their Uses
US2017246254A1
Lyophilised pharmaceutical formulation and its use
AU2014217753A1
A method for determining acute respiratory distress syndrome (ARDS) related biomarkers, a method to monitor the development and treatment of ARDS in a patient
US2013217033A1
Biomarker for monitoring development of diseases and assessing the efficacy of therapies
FI20090161A0
New cell and therapeutical and diagnostic methods based on it
FI20070795A0
A new biomarker for monitoring disease development and assessing the effectiveness of therapies
FI20060768A0
Compositions especially suitable for treating or preventing metabolic syndrome
FI20051003A0
A method of treating or preventing an ischemic reperfusion injury or multiple organ disorder
FI20050640A0
Compounds for treating or preventing diseases or disorders related to amine oxidases
CA2549029A1
Compositions for treatment or prevention of metabolic syndrome
US2006198821A1
Method for inducing an elevated level of adenosine in an individual
FI20040136A0
Compositions especially suitable for diabetics
FI20031927A0
Therapeutically active substances and their use
US7354577B2
Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1) and uses thereof
